Each year, Rare Disease Day aims to raise awareness of rare diseases and encourage positive change to patients’ lives. A disease is considered rare when it affects fewer than 1 in 2,000 people and there are 300 million people with rare diseases across the world.1 On Rare Disease Day 2023, we want to celebrate the […]
The Novo Holdings Venture Investments team has published its 2023 newsletter today. It is one of the largest and most active international life science venture investors with a track record of over 20 years investing in novel therapies. For more information, please see Venture Investments 2023 Newsletter.
Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]
Over US$ 550 million raised by portfolio companies in 2021 IO Biotech IPO on US NASDAQ Forendo Pharma acquired for nearly US$ 1 billion Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates Hemab raised US$ 50 million Series A to […]
Funds will be used to support the development of pioneering mammary biotechnology to bring a novel infant feeding option to market that better meets infants’ nutritional needs Syndicate includes leading clean tech and food tech investors Copenhagen, Denmark – 20 October 2021 – Novo Holdings, a leading international life science investor, today announces it has led […]